Hyaline cartilage is an essential component for the form and function of articulating joints, such as the knee. While the ideal management of chondral defects continues to be investigated, it is known that hyaline articular cartilage has limited capacity for healing due, in part, due to its poor intrinsic blood supply. Therefore, the risk of symptoms (pain, effusion, decreased activity, loss of function) related to chondral defects and the likelihood of lesion progression to eventual osteoarthritis remains pervasive.1,2 With increases in the annual incidence reported at up to 5%, there are between 30,000 and 100,000 chondral repair procedures that are performed yearly in the United States. 3,4 Currently, chondral lesions have been hypothesized
